Document Detail

The effects of spironolactone monotherapy on blood pressure and myocardial remodeling in spontaneously hypertensive rats: a stereological study.
MedLine Citation:
PMID:  12566986     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the cardiac structure of spontaneously hypertensive rats (SHRs) treated with different doses of spironolactone. Twenty SHRs were separated into four groups and treated for 13 weeks, as follows: one control group and three spironolactone treatment groups receiving doses of 5, 10 or 30 mg/kg/day. The spironolactone treatment either attenuated or prevented the tendency for increased blood pressure. However, the myocardial structure was not significantly affected by the spironolactone monotherapy treatment (all doses); it showed hypertrophied cardiac myocytes, focal areas of reactive fibrosis, inflammatory infiltrate and a decrease in the density of intramyocardial microvessels. None of the cardiac myocyte stereological parameters in the left ventricular myocardium showed significant differences among the SHR groups. The cardiac myocyte volume density was around 80%, the cardiac myocyte surface density varied from 3.6 to 4.1 x 10(4) mm2/mm3 and the cardiac myocyte mean cross-sectional area varied from 351 to 415 micro m2. The connective tissue volume density of the SHRs treated with the highest dose of spironolactone was 75% lower than in the control SHRs, and this was the only significant difference found for this parameter among SHR groups. The intramyocardial vessels showed some differences when the control SHRs and the other SHRs were compared. The lowest intramyocardial vessel volume density was found in the control group (more than 20% lower than that in the treated SHRs), but no significant difference was detected among the treated SHRs (all doses). The intramyocardial vessel length density (Lv[v]) and surface density (Sv[v]) showed a similar tendency, being significantly greater in the treated SHRs than in the control rats. The Lv[v] was 45% greater in the high-dose spironolactone group than in the control group, and it was 28% greater in the high-dose spironolactone SHRs than in the other treated SHRs. The Sv[v] was 50% greater in the high-dose spironolactone SHRs than in both control and low-dose spironolactone SHRs. Long-term spironolactone monotherapy showed a partial effect in the preservation of intramyocardial vessels and also in the attenuation of interstitial fibrosis.
Carlos Alberto Mandarim-de-Lacerda; Leila Maria Meirelles Pereira
Related Documents :
1101646 - Arterial pressure, cardiac output and systemic resistance before and after pithing in n...
7485536 - Autoregulation of zonal glomerular filtration rate and renal blood flow in spontaneousl...
15479856 - Interactions of tgf-dependent and myogenic oscillations in tubular pressure.
3816086 - Na+, k+ and water balance in young spontaneously hypertensive rats: relationship to blo...
15897926 - Relating drug-induced changes in carotid artery mechanics to cardiovagal and sympatheti...
21627516 - Sole depth and weight-bearing characteristics of the palmar surface of the feet of fera...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of biomedical science     Volume:  10     ISSN:  1021-7770     ISO Abbreviation:  J. Biomed. Sci.     Publication Date:    2003 Jan-Feb
Date Detail:
Created Date:  2003-02-04     Completed Date:  2003-11-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9421567     Medline TA:  J Biomed Sci     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  50-7     Citation Subset:  IM    
Copyright Information:
Copyright 2003 National Science Council, ROC and S. Karger AG, Basel
Laboratory of Morphometry and Cardiovascular Morphology, Biomedical Centre, Institute of Biology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*
Cardiotonic Agents / administration & dosage,  pharmacology
Diuretics / administration & dosage,  pharmacology*
Dose-Response Relationship, Drug
Fibrosis / pathology
Heart / drug effects*
Inflammation / pathology
Microcirculation / drug effects
Myocardium / pathology*
Myocytes, Cardiac / drug effects,  pathology
Rats, Inbred SHR
Spironolactone / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Cardiotonic Agents; 0/Diuretics; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The apoptotic action of the retinoid CD437/AHPN: diverse effects, common basis.
Next Document:  Nitric oxide mediates lung injury induced by ischemia-reperfusion in rats.